Company: SCLXW
Filing Date: 2025-08-04
Form Type: S-1
Source: 0001193125-25-172703
Chunk: 198

Company: Scilex Holding Co
Filing Date: 2025-08-04
Form: S-1
Chunk 198
---
 |   4,340 |
| Tranche B Notes (outstanding principal balance: $37.0 million, $38.0 million, and $38.0 million as of March 31, 2025, December 31, 2024 and 2023, respectively) |     |           | 24,480 |     |              | 23,560 |     |              |       — |
| Purchased Revenue Liability                                                                                                                                     |     |           |  7,300 |     |              |  6,800 |     |              |       — |
| Revolving Credit Facility                                                                                                                                       |     |           |      — |     |              |      — |     |              |  17,038 |
| Deferred Consideration with Romeg                                                                                                                               |     |           |  2,780 |     |              |  2,895 |     |              |   3,386 |
| Total indebtedness                                                                                                                                              |     | $         | 49,522 |     | $            | 45,416 |     | $            | 128,853 |

Debt Financings The Oramed Note As of March 31, 2025, the fair value of the Oramed Note outstanding was $15.0 million pursuant to the Scilex-Oramed SPA (see Note 7 titled “ Debt” to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for additional information). Convertible Debentures We fully repaid the Convertible Debentures in March 2024 (see Note 7 titled “ Debt” to our consolidated financial statements included elsewhere in this prospectus for additional information). Tranche B Notes As of March 31, 2025, the fair value of the Tranche B Notes outstanding was $24.5 million pursuant to the Tranche B Securities Purchase Agreement (see Note 7 titled “ Debt” to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for additional information). Purchased Revenue Liability As of March 31, 2025, the fair value of the purchased revenue liability was $7.3 million pursuant to the ZTlido Royalty Purchase Agreement and Gloperba-Elyxyb Royalty Purchase Agreement (see Note 7 titled 127

“Debt” to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for additional information).

Revolving Facility

We fully repaid the Revolving Facility in